Exploring High Growth Tech Stocks In January 2025

In the last week, the United States market has been flat, but it has seen a significant rise of 25% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.36%	24.28%	★★★★★★
Ardelyx	21.09%	55.29%	★★★★★★
AsiaFIN Holdings	51.75%	82.69%	★★★★★★
AVITA Medical	33.20%	51.87%	★★★★★★
TG Therapeutics	29.48%	43.58%	★★★★★★
Bitdeer Technologies Group	51.06%	122.94%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.37%	56.70%	★★★★★★
Travere Therapeutics	30.46%	62.05%	★★★★★★

Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

GDS Holdings (NasdaqGM:GDS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: GDS Holdings Limited, along with its subsidiaries, specializes in the development and operation of data centers across the People's Republic of China, with a market capitalization of approximately $4.27 billion.

Operations: GDS focuses on the design, build-out, and operation of data centers in China, generating revenue primarily from these activities. With a reported revenue of CN¥10.98 billion from this segment, the company plays a significant role in supporting digital infrastructure within the region.

GDS Holdings, navigating through a challenging landscape, reported a significant reduction in net loss to CNY 192.34 million in Q3 2024 from CNY 421.18 million the previous year, reflecting improved operational efficiency. Despite current unprofitability, the company is poised for growth with expected revenue increases at an annual rate of 14.8%, outpacing the US market's 8.9%. This growth trajectory is underpinned by robust demand for data center services amidst an expanding digital economy, although it faces headwinds from a highly volatile share price and ongoing legal challenges that could influence investor sentiment. The firm's focus on scaling operations and controlling costs suggests potential for profitability within three years, aligning with market expectations for above-average growth.

• Click here to discover the nuances of GDS Holdings with our detailed analytical health report.

• Assess GDS Holdings' past performance with our detailed historical performance reports.

Ascendis Pharma (NasdaqGS:ASND)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ascendis Pharma A/S is a biopharmaceutical company dedicated to developing therapies for unmet medical needs, with a market capitalization of $7.74 billion.

Operations: Ascendis Pharma A/S generates revenue primarily from its biotechnology segment, totaling €327.43 million.

Amidst a legal battle over patent infringement with BioMarin, Ascendis Pharma continues to innovate in the biotech sphere, evidenced by their recent positive trial outcomes for TransCon hGH in Turner syndrome. This innovation is underscored by a robust R&D commitment, with expenses reaching €57.83 million this quarter, reflecting an increase from last year's €48.03 million. Despite current unprofitability, Ascendis projects significant growth with expected annual revenue increases of 35.2%, positioning it well above the US market average of 8.9%. The company's strategic partnerships, like that with Novo Nordisk to expand into metabolic and cardiovascular diseases using its TransCon technology platform, further signal strong future prospects in high-growth biotech sectors.

• Click here and access our complete health analysis report to understand the dynamics of Ascendis Pharma.

• Learn about Ascendis Pharma's historical performance.

Incyte (NasdaqGS:INCY)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for hematology/oncology, inflammation, and autoimmunity globally, with a market cap of approximately $14.09 billion.

Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.08 billion. The company's focus on therapeutics for hematology/oncology and related areas drives its business operations both in the U.S. and internationally.

Incyte's recent FDA approval of Niktimvo for chronic GVHD marks a significant milestone, showcasing its commitment to addressing complex medical needs through innovative therapies. This approval, based on the AGAVE-201 trial results published in the New England Journal of Medicine, underscores Incyte's focus on developing targeted treatments that offer new hope to patients with limited options. The company's dedication is further evident in its R&D spending which consistently supports its pipeline development, ensuring sustained growth and innovation within the biotech sector. With a robust strategy for expanding treatment horizons and supporting patient access through IncyteCARES, Incyte is poised to enhance its impact in high-stakes medical areas.

• Dive into the specifics of Incyte here with our thorough health report.

• Gain insights into Incyte's historical performance by reviewing our past performance report.

Where To Now?

• Unlock our comprehensive list of 232 US High Growth Tech and AI Stocks by clicking here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com